Estamos no ar no ! Saiba mais
ícone de PACB

Pacific Biosciences
PACB

1,73 USD
-0,23
11,73%
No fechamento Atualizado 16 de out. 16:00 EDT
Pré-mercado
Após o fechamento do mercado
1,73
0,00
0%
1 dia
-11,73%
5 dias
-22,77%
1 mês
29,1%
3 meses
16,11%
6 meses
6,13%
No acumulado do ano
-5,98%
1 ano
-1,7%
5 anos
-92,88%
10 anos
-79,65%
 

Sobre: Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.

Funcionários: 485

Saúde Dispositivos médicos

Notícias

Positivo
Neutro
Negativo
Sentimento 3 meses
Positivo 24,1%
Neutro 55,2%
Negativo 20,7%
Neutro
Zacks Investment Research
anteontem
Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors
In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.99, indicating a -2.93% shift from the previous trading day.
Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors
Neutro
GlobeNewsWire
anteontem
PacBio to Report Third Quarter 2026 Financial Results on November 4, 2026
MENLO PARK, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2026 financial results on Wednesday, November 4, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
PacBio to Report Third Quarter 2026 Financial Results on November 4, 2026
Positivo
Zacks Investment Research
há 3 dias
PacBio Teams With TychoBio to Advance AI-Driven RNA Therapeutics
PACB partners with TychoBio to harness AI and long-read RNA sequencing for rare disease therapies, aiming to improve drug efficacy and safety through advanced data models.
PacBio Teams With TychoBio to Advance AI-Driven RNA Therapeutics
Neutro
Zacks Investment Research
há 8 dias
Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today
The latest trading day saw Pacific Biosciences of California (PACB) settling at $2.3, representing a -15.44% change from its previous close.
Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today
Neutro
GlobeNewsWire
há 10 dias
PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics
PacBio Kinnex sequencing will generate full-length transcript data to help advance TychoBio's drug discovery models PacBio Kinnex sequencing will generate full-length transcript data to help advance TychoBio's drug discovery models
PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics
Neutro
Zacks Investment Research
há 14 dias
Pacific Biosciences of California (PACB) Rises Higher Than Market: Key Facts
Pacific Biosciences of California (PACB) concluded the recent trading session at $2.54, signifying a +1.2% move from its prior day's close.
Pacific Biosciences of California (PACB) Rises Higher Than Market: Key Facts
Neutro
Schaeffers Research
há 15 dias
3 Biotech Stocks Put Traders Are Targeting Today
Nektar Therapeutics (NASDAQ:NKTR), Quantum-Si Inc (NASDAQ:QSI), and Pacific Biosciences of California Inc (NASDAQ:PACB) are all attracting elevated options activity today, as biotech stocks make volatile moves.
3 Biotech Stocks Put Traders Are Targeting Today
Positivo
Zacks Investment Research
há 21 dias
Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know
In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.62, marking a +2.53% move from the previous day.
Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know
Positivo
MarketBeat
há 26 dias
Pacific Biosciences Targets Clinical Growth, $40M Savings With HiFi Sequencing Push
Pacific Biosciences of California NASDAQ: PACB is maintaining its existing strategy while sharpening execution around clinical genomics, cost controls and the rollout of products designed to improve sequencing economics, Chief Executive Officer Mark Van Oene said during a Morgan Stanley discussion.
Pacific Biosciences Targets Clinical Growth, $40M Savings With HiFi Sequencing Push
Positivo
Zacks Investment Research
há 29 dias
Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today
In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.38, indicating a +2.99% shift from the previous trading day.
Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today
Ver ranking de notícias
Gráficos de preços implementados com Lightweight Charts™